Browse diseases

…ons This study showed that while more than 70% of patients with ES-SCLC received ICI-containing regimens as first-line treatment, progn…

…gnancies including melanoma, squamous cell carcinoma (SCC), and Merkel cell carcinoma (MCC). However, the concurrent use of ICIs and immunosuppressan…

…es NK cell activation and improves their therapeutic potential. AML, particularly in relapsed or refractory cases, remains a signif…

…al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022;28:144–53.Koo KC, Pa…

…4.Conclusions A single sarilumab dose before ubamatamab reduced CRS incidence and severity. Pharmacokinetic and pharmacodynamic fin…

…ansion study is evaluating CHS-114 in advanced solid tumors and head and neck squamous cell carcinoma (HNSCC). CHS-114 has demonstrated an acceptable safety profile …

…or regressions and a low incidence of Grade 3/4 adverse events. Melanoma patients with primary resistance to prior doublet immune checkp…

…ell therapy remains less effective against solid tumors such as neuroblastoma (NB) than hematological malignancies. Key obstacles for CAR T c…

…:62-68.Chapuis AG, Ragnarsson GB, Nguyen HN, et al. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire cen…

… NSCLC cells. For T cell suppression assays, M-MDSCs from human NSCLC were cultured with autologous T cells stimulated with anti-CD3 …

…reatment, toxicity, and fertility characteristics of young male melanoma patients treated with immune checkpoint inhibitors (n=38)…

…rrow niche alterations and hematopoietic clonal dynamicsResults Melanoma tumor cells infiltrate the bone marrow early, with disseminated…